Page last updated: 2024-10-31

mirtazapine and Guillain-Barre Syndrome

mirtazapine has been researched along with Guillain-Barre Syndrome in 1 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Künzel, H1

Other Studies

1 other study available for mirtazapine and Guillain-Barre Syndrome

ArticleYear
[Use of psychotropic drugs in patients with chronic pain].
    Revue medicale suisse, 2014, Jan-29, Volume: 10, Issue:415

    Topics: Chronic Pain; Cortisone; Depression; Guillain-Barre Syndrome; Humans; Mianserin; Middle Aged; Mirtaz

2014